

Yoshinobu Saito

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2217684/publications.pdf>

Version: 2024-02-01

51
papers

873
citations

471509

17
h-index

526287

27
g-index

55
all docs

55
docs citations

55
times ranked

1492
citing authors

#	ARTICLE	IF	CITATIONS
1	Pirfenidone inhibits fibrocyte accumulation in the lungs in bleomycin-induced murine pulmonary fibrosis. <i>Respiratory Research</i> , 2014, 15, 16.	3.6	98
2	Reduced incidence of lung cancer in patients with idiopathic pulmonary fibrosis treated with pirfenidone. <i>Respiratory Investigation</i> , 2018, 56, 72-79.	1.8	52
3	LONG-TERM INHALATION OF DIESEL EXHAUST AFFECTS CYTOKINE EXPRESSION IN MURINE LUNG TISSUES: COMPARISON BETWEEN LOW- AND HIGH-DOSE DIESEL EXHAUST EXPOSURE. <i>Experimental Lung Research</i> , 2002, 28, 493-506.	1.2	48
4	Î2-catenin-dependent transcription is central to Bmp-mediated formation of venous vessels. <i>Development (Cambridge)</i> , 2015, 142, 497-509.	2.5	48
5	EFFECTS OF DIESEL EXHAUST ON MURINE ALVEOLAR MACROPHAGES AND A MACROPHAGE CELL LINE. <i>Experimental Lung Research</i> , 2002, 28, 201-217.	1.2	42
6	Current status of DILD in molecular targeted therapies. <i>International Journal of Clinical Oncology</i> , 2012, 17, 534-541.	2.2	37
7	Radiologic features of pneumonitis associated with nivolumab in non-small-cell lung cancer and malignant melanoma. <i>Future Oncology</i> , 2019, 15, 1911-1920.	2.4	36
8	Immune checkpoint inhibitor-associated interstitial lung diseases correlate with better prognosis in patients with advanced non-small cell lung cancer. <i>Thoracic Cancer</i> , 2020, 11, 1052-1060.	1.9	36
9	Clinical features, anti-cancer treatments and outcomes of lung cancer patients with combined pulmonary fibrosis and emphysema. <i>Lung Cancer</i> , 2014, 85, 258-263.	2.0	35
10	Exosome-Derived microRNA-22; Ameliorates Pulmonary Fibrosis by Regulating Fibroblast-to-Myofibroblast Differentiation in Vitro and in Vivo. <i>Journal of Nippon Medical School</i> , 2020, 87, 118-128.	0.9	34
11	Real-World Evaluation of Factors for Interstitial Lung Disease Incidence and Radiologic Characteristics in Patients With EGFR T790M-positive NSCLC Treated With Osimertinib in Japan. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1893-1906.	1.1	32
12	Resolution of bleomycin-induced murine pulmonary fibrosis via a splenic lymphocyte subpopulation. <i>Respiratory Research</i> , 2018, 19, 71.	3.6	26
13	Pembrolizumab-induced agranulocytosis in a pulmonary pleomorphic carcinoma patient who developed interstitial lung disease and ocular myasthenia gravis. <i>Oxford Medical Case Reports</i> , 2018, 2018, omy094.	0.4	23
14	A Case of Pneumocystis Pneumonia Associated with Everolimus Therapy for Renal Cell Carcinoma. <i>Japanese Journal of Clinical Oncology</i> , 2013, 43, 559-562.	1.3	22
15	Nintedanib modulates surfactant protein-D expression in A549 human lung epithelial cells via the c-Jun N-terminal kinase-activator protein-1 pathway. <i>Pulmonary Pharmacology and Therapeutics</i> , 2015, 32, 29-36.	2.6	20
16	Real-world use of osimertinib for epidermal growth factor receptor T790M-positive non-small cell lung cancer in Japan. <i>Japanese Journal of Clinical Oncology</i> , 2020, 50, 909-919.	1.3	19
17	Tiotropium Ameliorates Symptoms in Patients with Chronic Airway Mucus Hypersecretion which is Resistant to Macrolide Therapy. <i>Internal Medicine</i> , 2008, 47, 585-591.	0.7	18
18	COPD advances in left ventricular diastolic dysfunction. <i>International Journal of COPD</i> , 2016, 11, 649.	2.3	18

#	ARTICLE	IF	CITATIONS
19	Prognostic Factors in the Acute Exacerbation of Idiopathic Pulmonary Fibrosis: A Retrospective Single-center Study. <i>Internal Medicine</i> , 2018, 57, 655-661.	0.7	17
20	Interstitial lung disease associated with nanoparticle albumin-bound paclitaxel treatment in patients with lung cancer. <i>Japanese Journal of Clinical Oncology</i> , 2019, 49, 165-173.	1.3	17
21	Cyclic mechanical stretch-induced oxidative stress occurs via a NOX-dependent mechanism in type II alveolar epithelial cells. <i>Respiratory Physiology and Neurobiology</i> , 2017, 242, 108-116.	1.6	16
22	XPLN is modulated by HDAC inhibitors and negatively regulates SPARC expression by targeting mTORC2 in human lung fibroblasts. <i>Pulmonary Pharmacology and Therapeutics</i> , 2017, 44, 61-69.	2.6	15
23	Treatment and relapse of interstitial lung disease in nivolumab-treated patients with non-small cell lung cancer. <i>Cancer Science</i> , 2021, 112, 1506-1513.	3.9	14
24	Rictor-targeting exosomal microRNA-16 ameliorates lung fibrosis by inhibiting the mTORC2-SPARC axis. <i>Experimental Cell Research</i> , 2021, 398, 112416.	2.6	12
25	Kikuchi-Fujimoto disease can present as delayed lymphadenopathy after COVID-19 vaccination. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, 2071080.	3.3	12
26	Pirfenidone exerts a suppressive effect on CCL18 expression in U937-derived macrophages partly by inhibiting STAT6 phosphorylation. <i>Immunopharmacology and Immunotoxicology</i> , 2016, 38, 464-471.	2.4	10
27	A case of interstitial lung disease with alveolar hemorrhage induced by pembrolizumab. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 5879-5883.	2.0	10
28	Safety and tolerability of combination therapy with pirfenidone and nintedanib for idiopathic pulmonary fibrosis: A multicenter retrospective observational study in Japan. <i>Respiratory Investigation</i> , 2021, 59, 819-826.	1.8	10
29	Granuloma-forming Interstitial Pneumonia Occurring One Year after the Start of Everolimus Therapy. <i>Internal Medicine</i> , 2013, 52, 263-267.	0.7	8
30	Anti-MDA5 antibody-positive rapidly progressive interstitial pneumonia without cutaneous manifestations. <i>Respiratory Medicine Case Reports</i> , 2019, 26, 193-196.	0.4	8
31	Radiographic features and poor prognostic factors of interstitial lung disease with nivolumab for non-small cell lung cancer. <i>Cancer Science</i> , 2021, 112, 1495-1505.	3.9	8
32	Body Mass Index and arterial blood oxygenation as prognostic factors in patients with idiopathic pleuroparenchymal fibroelastosis. <i>Sarcoidosis Vasculitis and Diffuse Lung Diseases</i> , 2017, 34, 35-40.	0.2	8
33	Fatal Pneumonia Associated with Temozolomide Therapy in Patients with Malignant Glioma. <i>Japanese Journal of Clinical Oncology</i> , 2012, 42, 632-636.	1.3	7
34	Pembrolizumab and salvage chemotherapy in EGFR T790M-positive non-small-cell lung cancer with high PD-L1 expression. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 5601-5605.	2.0	7
35	<i>Acinetobacter baumannii</i> can be transferred from contaminated nitrile examination gloves to polypropylene plastic surfaces. <i>American Journal of Infection Control</i> , 2019, 47, 1171-1175.	2.3	7
36	A Case of Bucillamine-induced Interstitial Pneumonia with Positive Lymphocyte Stimulation Test for Bucillamine Using Bronchoalveolar Lavage Lymphocytes. <i>Internal Medicine</i> , 2007, 46, 1739-1744.	0.7	6

#	ARTICLE	IF	CITATIONS
37	Interstitial lung disease associated with amrubicin chemotherapy in patients with lung cancer: a single institutional study. Japanese Journal of Clinical Oncology, 2016, 46, 674-680.	1.3	6
38	Elotuzumab-induced interstitial lung disease: the first case report. Japanese Journal of Clinical Oncology, 2018, 48, 491-494.	1.3	6
39	Successful Treatment with Afatinib after Osimertinib-induced Interstitial Lung Disease in a Patient with EGFR-mutant Non-small-cell Lung Cancer. Internal Medicine, 2021, 60, 591-594.	0.7	6
40	Organizing Pneumonia after Nivolumab Treatment in a Patient with Pathologically Proven Idiopathic Pulmonary Fibrosis. Journal of Nippon Medical School, 2019, 86, 43-47.	0.9	4
41	Analyses of alveolar epithelial injury via lipid-related stress in mammalian target of rapamycin inhibitor-induced lung disease. Laboratory Investigation, 2019, 99, 853-865.	3.7	4
42	Granuloma-forming interstitial pneumonia induced by nivolumab: a possible immune-related adverse event of the lung. International Cancer Conference Journal, 2017, 6, 131-134.	0.5	3
43	Pulmonary embolism and deep vein thrombosis in eosinophilic granulomatosis with polyangiitis successfully treated with rivaroxaban. Respiratory Medicine Case Reports, 2018, 25, 33-35.	0.4	3
44	Efficacy of Corticosteroid Therapy in Non-severe COVID-19 Patients with Severe Risk Factors who do not Require Supplemental Oxygen. Journal of Nippon Medical School, 2022, , .	0.9	2
45	Crizotinib-induced severe ulcerative esophagitis three years after chemoradiotherapy. International Cancer Conference Journal, 2015, 4, 221-224.	0.5	1
46	Severe Pneumonitis with Alveolar Hemorrhage Associated with Herbal Medicines: A Case Report. Journal of Nippon Medical School, 2019, 86, 296-300.	0.9	1
47	æ°—ç®ªæ”æ¼¼µç—‡. Nihon Ika Daigaku Igakkai Zasshi, 2018, 14, 72-80.	0.0	0
48	A Possible, Non-Invasive Method of Measuring Dynamic Lung Compliance in Patients with Interstitial Lung Disease Using Photoplethysmography. Journal of Nippon Medical School, 2021, 88, 326-334.	0.9	0
49	A Neuroendocrine Carcinoma from a Difficult-to-detect Primary Site Presenting as Neck and Mediastinal Lymphadenopathy. Nihon Ika Daigaku Igakkai Zasshi, 2012, 8, 162-167.	0.0	0
50	A Case of Simultaneous Onset of Acute Exacerbation of Idiopathic Pulmonary Fibrosis and Pulmonary Tuberculosis. Nihon Ika Daigaku Igakkai Zasshi, 2014, 10, 111-114.	0.0	0
51	Effect of Adding Inhaled Corticosteroid to Long-Acting Muscarinic Antagonist/Long-Acting Beta-Agonist Therapy Among Patients With Chronic Obstructive Pulmonary Disease. Cureus, 2021, 13, e19168.	0.5	0